Upregulated Tie2 expression in plasma: a potential non-invasive biomarker for the diagnosis of breast cancer

2021 ◽  
Vol 32 (2) ◽  
pp. 39-47
Author(s):  
Qingzhu Song ◽  
Fenglan Zhang ◽  
Tian Yuan ◽  
Yulong Wei
Keyword(s):  
Breast Cancer ◽  
Non Invasive

Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model

2021 ◽  
Author(s):  
Aditya Bansal ◽  
Mukesh K. Pandey ◽  
Whitney Barham ◽  
Xin Liu ◽  
Susan M. Harrington ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Model ◽  
Melanoma Tumor ◽  
Non Invasive

scholarly journals Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Andrea DeCensi ◽  
Harriet Johansson ◽  
Thomas Helland ◽  
Matteo Puntoni ◽  
Debora Macis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Low Dose ◽  
Cancer Recurrence ◽  
Phase Iii ◽  
Cyp2d6 Genotype ◽  
Phase Iii Trial ◽  
Reactive Protein ◽  
Non Invasive ◽  
Tamoxifen Metabolites ◽  
Dose Trial

AbstractLow-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 nM) and recurrence, but no association with CYP2D6 was shown in the NSABP P1 and P2 prevention trials. We studied the association of CYP2D6 genotype and tamoxifen metabolites with tumor biomarkers and recurrence in a randomized phase III trial of low-dose tamoxifen. Median (IQR) endoxifen levels at year 1 were 8.4 (5.3–11.4) in patients who recurred vs 7.5 (5.1–10.2) in those who did not recur (p = 0.60). Tamoxifen and metabolites significantly decreased C-reactive protein (CRP, p < 0.05), and a CRP increase after 3 years was associated with higher risk of recurrence (HR = 4.37, 95% CI, 1.14–16.73, P = 0.03). In conclusion, endoxifen is below 9 nM in most subjects treated with 5 mg/day despite strong efficacy and there is no association with recurrence, suggesting that the reason for tamoxifen failure is not poor drug metabolism. Trial registration: ClinicalTrials.gov, Identifier: NCT01357772.

scholarly journals Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review

2020 ◽  
Vol 21 (16) ◽  
pp. 5834
Author(s):  
Anna Maria Grimaldi ◽  
Silvia Nuzzo ◽  
Gerolama Condorelli ◽  
Marco Salvatore ◽  
Mariarosaria Incoronato
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Prognostic Biomarker ◽  
Survival Rates ◽  
Prognostic Significance ◽  
Unmet Need ◽  
Non Invasive ◽  
Clinicopathological Significance ◽  
Present Systematic Review

There is an unmet need for novel non-invasive prognostic molecular tumour markers for breast cancer (BC). Accumulating evidence shows that miR-155 plays a pivotal role in tumorigenesis. Generally, miR-155 is considered an oncogenic miRNA promoting tumour growth, angiogenesis and aggressiveness of BC. Therefore, many researchers have focused on its use as a prognostic biomarker and therapeutic target. However, its prognostic value for BC patients remains controversial. To address this issue, the present systematic review aims to summarize the available evidence and give a picture of a prognostic significance of miR-155 in BC pathology. All eligible studies were searched on PubMed and EMBASE databases through various search strategies. Starting from 289 potential eligible records, data were examined from 28 studies, comparing tissue and circulating miR-155 expression levels with clinicopathological features and survival rates in BC patients. We discuss the pitfalls and challenges that need to be assessed to understand the power of miR-155 to respond to real clinical needs, highlighting the consistency, robustness or lack of results obtained to sate in translating this molecule to clinical practice. Our paper suggests that the prognostic role of miR-155 in the management of BC needs to be further verified.

scholarly journals TLR4 Ligand/H2O2 Enhances TGF-β1 Signaling to Induce Metastatic Potential of Non-Invasive Breast Cancer Cells by Activating Non-Smad Pathways

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e65906 ◽  
Author(s):  
Yuan-Hong Zhou ◽  
Sheng-Jun Liao ◽  
Dong Li ◽  
Jing Luo ◽  
Jing-Jing Wei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Invasive Breast Cancer ◽  
Breast Cancer Cells ◽  
Metastatic Potential ◽  
Non Invasive ◽  
Tlr4 Ligand ◽  
Tgf Β1

Pathological features predictive of local recurrence after management by conservation of invasive breast cancer: importance of non-invasive carcinoma

1992 ◽  
Vol 25 (3) ◽  
pp. 176-180 ◽  
Author(s):  
D.A. Paterson ◽  
T.J. Anderson ◽  
W.J.L. Jack ◽  
G.R. Kerr ◽  
A. Rodger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Invasive Breast Cancer ◽  
Invasive Carcinoma ◽  
Pathological Features ◽  
Non Invasive
Sign in / Sign up

Export Citation Format

Share Document